Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Mark Konrad who wrote (32823)	8/24/2000 1:56:40 PM
From: Paul Berliner	Read Replies (1) \| Respond to of 57584

Look what I found on ATIS!! they hold STEM CELL patents: sec.gov In October 1999, the Company received a U.S. patent covering three-dimensional stromal tissue cultures containing mesenchymal stem cells and methods for preparing these cultures. Human mesenchymal stem cells are a specialized type of stem cell and are believed to be the progenitors, or parent cells, responsible for the formation of cartilage, bone, muscle, tendon, ligament or other connective tissues. The patent covers culturing mesenchymal stem cells in vitro on any biodegradable or non-biodegradable three-dimensional framework, including a mesh or sponge. This patent complements the Company's patent issued in May 1999 which covers the growth of living cartilage from mesenchymal stem cells, chondroprogenitor cells and umbilical cord cells as well as mature chondrocytes and fibroblasts. This patent expires in 2006.